

**899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002**

December 5, 2019

9:30am-11:30 am

OPEN SESSION AGENDA

Board of Pharmacy Mission Statement:

"To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians."

CALL TO ORDER:

PRESIDING:

BOARD MEMBERSHIP/ATTENDANCE:

[illegible]

Open Session Agenda

Quorum:

Introduction:	Honoring of Board Member, James Appleby, RPh. of years of services as a DC Board of Pharmacy Member	
1205-O-01	<u>Approval of the Open Session Meeting Minutes</u> (a) October 3, 2019 (b) November 7, 2019	
<u>Consent Agenda</u>	None	
<u>Executive Director Report</u>	<u>Licensing Report</u> Statistics Prescription Monitoring Program Update Opioid Strategic Plan NABP Updates-Pre-MPJE DC Board of Pharmacy CE Audit Update NARCAN Pilot-Free NARCAN at Select DC Pharmacies Pharmaceutical Detailer Renewal Starting January 1, 2020	
<u>FYI to the Board</u>		
1205-O-02	Health Priority Continuing Education Requirements (a) Public Notice-Identifying Public Health Issues for Continuing Education	Dr. Shauna White
<u>Assistant General Counsel Report</u>		Ms. Carla Williams
1205-O-03	Opioid Labeling Amendment Act 2019 Bill The Opioid Labeling Amendment Act 2019 is amending the District of Columbia Certificate of Need Act of 1980 to combat opioid abuse by requiring prescription opioid medications to include a statement that the drug is an opioid and that opioids may cause dependence, addiction, or overdose. This information is brought before The Board for review and feedback. (a) Bill B23-0535-Introduction	

<u>Subcommittee Report</u>		
	<u>Legislative and Regulatory</u>	
1205-O-04	Defending Access to Women's Health Care Services Amendment Act of 2017	Mr. Alan Friedman
1205-O-05	<u>Communications Subcommittee Report</u>	Dr. Ashley Bow
NABP E-Newsletter	<p><u>November 6, 2019</u></p> <p>FDA Issues Report on Root Causes and Solutions to Drug Shortages</p> <p>DEA Issues Warning Over Counterfeit Prescription Pills From Mexico</p> <p>Acting FDA Commissioner Returns to National Cancer Institute</p> <p>SAMHSA Launches New Substance Abuse Treatment Locator Website</p> <p>FDA Drug Topics Webinar Will Be Held on November 19</p> <p><u>November 13, 2019</u></p> <p>FDA Releases Draft Best Practice Document for Postmarket Drug Surveillance</p> <p>Illinois Considering Regulatory Changes to Relieve Pharmacists' Heavy Workloads</p> <p>DEA Reports Strong Participation During Latest Prescription Drug Take-Back Day</p> <p>Virginia Woman Pleads Guilty to Making Large Amounts of Illicitly Manufactured Fentanyl, Heroin</p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/</p>	Dr. Tamara McCants
<u>Presentation</u>		
1205-O-06	<u>Washington, DC Pharmacy Robberies</u>	Mr. Countee Gilliam
<u>Matters for Board Consideration</u>		
1205-O-07	<p>Draft of a ADA Testing Accommodation Policy</p> <p>The DC Board of Pharmacy is interested in establishing guidelines for candidates that are requesting for exam testing accommodations under the Americans with Disabilities Act.</p>	

	(a) Draft Policy	
1205-O-08	AMA CME Credits for Pharmacy Technicians This matter is brought before the Board for the Board's approval to accept Continuing Medical Education (CME) credits by the American Medical Association for Pharmacy Technicians (a) DC Municipal Regulations for Pharmacy Technicians Chapter 99	
<u>Public Comments</u>		
Motion to Adjourn the Open Session	"Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)." (Roll Call Vote)	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at __: __

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.